口服烟酰胺与皮肤科患者心血管事件风险降低相关:TriNetX队列研究
本研究基于TriNetX平台开展回顾性队列研究,纳入≥2处非黑色素瘤皮肤癌或大疱性类天疱疮且开始口服烟酰胺(≥500 mg)的患者,与未使用者1:1匹配。匹配后每组3231例,烟酰胺使用与ST段抬高型心肌梗死、外周血管疾病和心脏骤停风险降低相关。
要点
- 口服烟酰胺≥500 mg与STEMI风险降低相关(RR 0.547)。
- 烟酰胺使用还与外周血管疾病和心脏骤停风险降低相关。
- 有动脉粥样硬化性心血管病史者 subgroup 分析结果一致。
核心结论
- 烟酰胺补充与特定类型心血管事件风险降低相关,支持在合适人群中使用。
研究设计与样本
- 回顾性队列研究,使用TriNetX平台,纳入≥2处非黑色素瘤皮肤癌或大疱性类天疱疮并开始口服烟酰胺(≥500 mg)的患者,与未使用者1:1匹配,匹配后每组3231例。
主要发现
- 按动脉粥样硬化性心血管病史进行的亚组分析显示一致的心血管获益。
临床怎么用
- 对于需要非黑色素瘤皮肤癌化学预防的合适患者,口服烟酰胺可能带来心血管获益。
局限性
- 观察性研究无法确立因果关系。
- 研究人群以白人为主且时间框架为3年,限制外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Niacinamide is frequently used for nonmelanoma skin cancer (NMSC) chemoprophylaxis. Recent studies raised concerns about cardiovascular risk associated with niacin metabolites. OBJECTIVE: To evaluate the association between oral niacinamide use and cardiovascular outcomes in patients with multiple NMSCs. METHODS: We conducted a retrospective cohort study using the TriNetX platform. Patients with ≥ 2 NMSCs or bullous pemphigoid who began taking oral niacinamide (≥ 500 mg) were matched 1:1 with niacinamide-naive controls. Outcomes included various major cardiovascular events. RESULTS: After matching, each cohort consisted of 3231 patients. Niacinamide use was associated with reduced risk of ST elevation myocardial infarction (risk ratio [RR]: 0.547, 95% confidence interval [CI]: 0.349-0.858, P = .008), peripheral vascular disease (RR: 0.741, 95% CI: 0.605-0.909, P = .004), and cardiac arrest (RR: 0.500, 95% CI: 0.275-0.909, P = .020). Subgroup analyses by atherosclerotic cardiovascular disease history showed consistent cardiovascular benefits. LIMITATIONS: As an observational study, causality cannot be established. The predominantly White study population and 3-year timeframe limit generalizability. CONCLUSION: Niacinamide supplementation is associated with reductions in certain types of cardiovascular events, supporting its use in appropriate patient populations.
引用
- Salem Y, Liaqat M, Gonna N, et al. Decreased risk of cardiovascular disease in dermatology patients taking niacinamide: A TriNetX cohort study. J Am Acad Dermatol. 2025. PMID: 41177359. doi:10.1016/j.jaad.2025.10.115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。